Skip to main content

Table 1 Summary information of studies included in the meta-analyses.

From: ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation

First author, Year, Country [ref] Study design, duration of FU Cohort description [No of patients (M/F), Ethnicity, Mean Age (SD), inclusion criteria] Restenosis definition criteria Intervention Gene-gene interaction assessed? (gene) Quality score
     Balloon angioplasty   
Volzke, 2000, Germany [17] cohort
6 months
511 (388/123), Caucasians, 60.6 (8.6), CAD patients undergoing elective PTCA of a previously untreated native coronary artery > 50% progression of the residual stenosis at FU PTCA-balloon No 35
Yoshida, 1999, Japan [18] cohort
5.21 (3.9) years
123 (nr), East Asians, 58.2 (10.2), MI patients undergoing PTCA discharged from hospital at the start of FU nr PTCA-balloon No 30
Kasi, 1996, Spain [19] cohort
6 months
69 (57/12), Caucasians, 58 (9.9), UA patients undergoing PTCA diameter stenosis > 50% at FU PTCA-balloon No 27
Kamitani, 1995, Japan [20] cohort
6 months
103 (103/00), East Asians, 52 (1), Primary PTCA for MI patients > 50% progression of the residual stenosis at FU PTCA-balloon No 27
Samani, 1995, UK [21] cohort
4 months
233 (194/39), nr, 56 (1), single-vessel PTCA in the Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) study > 50% progression of the residual stenosis at FU PTCA-balloon No 34
van Bockxmeer, 1995, Australia [22] cohort
6 months
207 (170/37), Caucasians, 57 (9), CAD patients undergoing elective PTCA > 50% progression of the residual stenosis at FU PTCA-balloon Yes (APOE) 33
Tsukada, 1997, Japan [23] cohort
3 months
96 (nr), East Asians, 60 (1.0), CAD patients undergoing elective PTCA diameter stenosis > 50% at FU PTCA-balloon No 28
Beohar, 1995, USA [24] cohort
3 months
89 (nr), Caucasians, 63.9 (10), CAD patients undergoing elective PTCA diameter stenosis > 50% at FU PTCA-balloon No 24
Zee, 2001, Spain [25] cohort
6 months
342 (305/37), Caucasians, 58.9 (9.6), CAD patients undergoing PTCA > 50% progression of the residual stenosis at FU PTCA-balloon No 37
Ohishi, 1993, Japan [26] cohort
6 months
82 (nr), East Asians, nr, MI patients undergoing primary PTCA > 50% progression of the residual stenosis at FU PTCA-balloon No 23
Hamon, 1998, France [37] cohort
6 months
271 (229/42), Caucasians, 60 (10), CAD patients undergoing PTCA diameter stenosis > 50% at FU PTCA-balloon Yes (AGT1R) 34
     Angioplasty with stent deployment   
Amant, 1997, France [30] cohort
6 months
146 (117/29), Caucasians, 60 (10) CAD patients undergoing PTCA diameter stenosis > 50% at FU PTCA-STENT No 37
Wijpkema, 2006, Netherlands [29] cohort
9 months
2888 (2050/838), Caucasians, 62 (11), CAD patients undergoing elective PTCA death from cardiac causes, MI attributable to target vessel and target vessel revascularization PTCA-STENT Yes (AGT, AGT1R, AGT2R, HMOX1) 35
Gomma, 2002, UK [31] cohort
6 months
205 (155/50), Caucasians, 59.4 (9.9), CAD patients undergoing PTCA diameter stenosis > 50% at FU PTCA-STENT No 27
Ruy, 2002, Korea [32] cohort
6 months
238 (178/60), East Asians, 59.5 (9.9), CAD patients undergoing PTCA diameter stenosis > 50% at FU PTCA-STENT Yes (CYP11B2, AGT) 32
Ribichini, 2004, Italy [33] cohort
6 months
897 (160/737), Caucasians, 61 (10), CAD patients undergoing PTCA diameter stenosis > 50% at FU PTCA-STENT No 33
Taniguchi, 2001, Japan [34] cohort
6 months
67 (50/17), East Asians, 65.2 (9.7), CAD patients undergoing PTCA > 50% progression of the residual stenosis at FU PTCA-STENT No 23
Koch, 2000, Germany [35] cohort
1 year
1850 (1458/392), Caucasians, 62.9 (10), CAD patients undergoing PTCA diameter stenosis > 50% at FU PTCA-STENT No 40
Gurlek, 2000, Turkey [36] cohort
6 months
132 (112/20), Turks, 53 (9), CAD patients undergoing PTCA diameter stenosis > 50% at FU PTCA-STENT No 29
Guneri, 2005, Turkey [43] cohort
9 months (2.9)
94 (59/35), Turks, 59.6 (9.9), CAD diabetic patients undergoing PTCA for stable angina pectoris diameter stenosis > 50% at FU PTCA-STENT No 26
     Angioplasty with ACEi treatment   
Ribichini, 2003, Italy [42] Cohort
6.3 (2.5) months
271 (nr), Caucasians, 61 (10), CAD patients undergoing PTCA diameter stenosis > 50% at FU PTCA-STENT + ACEi No 35
Okamura, 1999, Japan [44] cohort
6 months
97 (84/13), East Asians, 60 (2), CAD patients undergoing PTCA for stable angina pectoris diameter stenosis > 50% at FU PTCA-balloon + Imidapril 5 mg No 29
Okumura, 2002, Japan [45] cohort
6 months
92 (73/19), East Asians, 64.3 (8.9), CAD patients undergoing PTCA diameter stenosis > 50% at FU PTCA-STENT + Quinapril 18 mg No 22
Ferrari, 2002, multicenter (Europe) [46] cohort
6 months
154 (119/35), Caucasians, 61 (9.9), CAD patients undergoing PTCA > 50% progression of the residual stenosis at FU PTCA-STENT + ACEi No 36
Jorgensen, 2001, Netherlands [49] cohort
6 months
369 (293/76), Caucasians, 59 (43–73), CAD patients undergoing PTCA for stable angina diameter stenosis > 50% at FU PTCA-STENT + ACEi No 40
  1. Abbreviations: DCA: directional coronary atherectomy, FU: follow-up, UA: unstable angina, MI: myocardial infarction, RCT: randomized controlled trial, ACEi: angiotensin converting enzyme inhibitors, nr: non-reported